Oncocyte CORP Form 4 insider transactions

Director Andrew Arno of Oncocyte Corp purchased 12,500 shares of common stock at an average price of $2.108 per share on December 26, 2024.

Oncocyte Corporation's Chief Financial Officer, Andrea James, purchased 20,000 shares of the company's common stock at a price of $2.29 per share.

Andrea James, CFO of Oncocyte Corp, reports the grant of stock options and restricted stock units (RSUs) following stockholder approval of an increase in shares available under the company's equity incentive plan.

Andrea James, CFO of Oncocyte Corp, purchased 33,670 shares of common stock in a private placement on October 2, 2024.

Broadwood Partners, L.P. acquired 1,315,339 shares of Oncocyte Corp common stock in a private placement for approximately $3.88 million.

Director Andrew Arno reports the acquisition of stock options in Oncocyte Corp.

Director Andrew J. Last acquired options to purchase 30,000 shares of Oncocyte Corp common stock on July 1, 2024.

Director Lou Silverman acquired 30,000 stock options in Oncocyte Corp on July 1, 2024.

Andrea James, CFO of Oncocyte Corp, was granted stock options and restricted stock units on June 20, 2024, subject to shareholder approval and certain vesting conditions.

James Yang Liu, a Senior Director at Oncocyte Corp, reports the acquisition of stock options.

Director Andrew Arno reports the acquisition of stock options in Oncocyte Corp.

Oncocyte Corp CEO and President Josh Riggs reports the acquisition of 90,000 options to purchase common stock.

Broadwood Partners, L.P. acquired 2,420,000 shares of Oncocyte Corp common stock in a private placement, while also seeing its Series A Convertible Preferred Stock redeemed by the issuer.

Oncocyte Corp CEO and President Josh Riggs purchased 3,390 shares of the company's common stock at $2.95 per share in a private offering on April 11, 2024.

Director Andrew Arno purchased 33,898 shares of Oncocyte Corp in a private offering at $2.95 per share.